Recent research indicates that a notable percentage of men diagnosed with Grade Group 1 (GG1) prostate cancer through biopsy may actually encounter higher cancer-specific risks than conventionally acknowledged, challenging the notion of categorizing GG1 as a non-cancerous condition. While proponents advocating for the removal of the cancer label from GG1 prostate cancer argue that pure GG1 identified during prostatectomy is seldom associated with metastasis, the frequency with which GG1 biopsies correlate with more aggressive disease and poorer long-term outcomes remains largely unknown. In a large-scale, population-based cohort study, researchers delved into Surveillance, Epidemiology, and End Results (SEER) data from 117,162 men diagnosed with localised GG1 prostate cancer between 2010 and 2020. Men were categorized based on National Comprehensive Cancer Network (NCCN) risk categories, and outcomes were evaluated using multivariable regression and competing risk models. The study’s key endpoints were prostate cancer-specific mortality and the incidence of adverse pathology at surgery.
Within the cohort, 9% exhibited favourable intermediate-risk disease, 3% had unfavourable intermediate-risk, and 4% were classified with high-risk disease, indicating that almost one in six men with GG1 disease did not fit into the low-risk group. The median age at diagnosis stood at 64 years. Among those with high-risk GG1, 60% showed adverse pathology during prostatectomy. Noteworthy findings included prostate cancer-specific mortality rates of 2.4% for unfavourable intermediate-risk GG1 and 4.7% for high-risk GG1, figures comparable to more aggressive Grade Group 2 (GG2) disease. Adjusted hazard ratios for prostate cancer mortality were notably elevated: 1.60 (95% CI: 1.30–1.96) for favourable intermediate-risk, 2.10 (95% CI: 1.53–2.89) for unfavourable intermediate-risk, and 3.58 (95% CI: 2.93–4.38) for high-risk GG1, all in comparison to low-risk GG1.
The research presents compelling evidence that GG1 prostate cancer does not uniformly exhibit an indolent nature. A significant subset of patients with biopsy GG1 disease experiences outcomes akin to those with higher-grade tumors, underscoring the importance of exercising caution in reclassification debates and meticulous risk stratification in clinical decision-making.
Key Takeaways:
– A substantial proportion of men diagnosed with Grade Group 1 (GG1) prostate cancer via biopsy may face higher cancer-specific risks than previously believed.
– Findings from a population-based cohort study reveal that nearly one in six men with GG1 disease do not fall within the low-risk category.
– Prostate cancer-specific mortality rates for high-risk GG1 are comparable to those of more aggressive Grade Group 2 (GG2) disease, emphasizing the need for careful risk assessment in clinical management.
– The study highlights the necessity of reevaluating the perceived risk levels associated with low-grade prostate cancer and the importance of personalized treatment approaches.
Read more on emjreviews.com